{"id":"8fae5840-b733-505c-9bb9-531c5e155a69","stable_key":"788beb7b-7928-5f89-83d4-5556abf3702c:fulvic-acid-lovo-scratch","predicate":"increases_assay_closure","statement":"MLG-A50 increased scratch closure in LoVo-cell assays.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"context_dependent","is_public":true,"mechanism_event_id":"50504472-c7f9-549c-b73b-6c201cfeb50f","mechanism_event_label":"A cultured monolayer closed its artificial gap faster.","subject":{"id":"eb6cc922-7af3-5247-91b1-3354be3141bb","slug":"mlg-a50-fulvic-formulation","display_name":"MLG-A50 alkaline fulvic/mineral formulation","entity_type_key":"chemical_species"},"object":{"id":"912fa65c-8278-5039-a594-6bd7f65fa1da","slug":"human-lovo-fa-scratch-closure","display_name":"Human LoVo scratch-assay closure under fulvic formulation exposure","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"50504472-c7f9-549c-b73b-6c201cfeb50f","stable_key":"788beb7b-7928-5f89-83d4-5556abf3702c:fulvic-acid-lovo-scratch-event","event_type":"observed_relationship","label":"A cultured monolayer closed its artificial gap faster.","description":"MLG-A50 increased scratch closure in LoVo-cell assays.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"eb6cc922-7af3-5247-91b1-3354be3141bb","slug":"mlg-a50-fulvic-formulation","display_name":"MLG-A50 alkaline fulvic/mineral formulation","entity_type_key":"chemical_species"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"912fa65c-8278-5039-a594-6bd7f65fa1da","slug":"human-lovo-fa-scratch-closure","display_name":"Human LoVo scratch-assay closure under fulvic formulation exposure","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"0aa6c0fc-8374-56e0-b172-6c40b6366d21","slug":"fulvic-acid","display_name":"Fulvic acid (heterogeneous humic fraction)","entity_type_key":"chemical_species"},"role":"context_participant","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""}]},"contexts":[{"dimension":"evidence_access","value_text":"Primary full text","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"2026 MLG-50/MLG-A50 study; fossil extracts contain fulvic fractions plus mineral/polyphenol components, stock pH about 1.97/12.1. Human colorectal adenocarcinoma LoVo cells; dilutions 1:8192 to 1:32768.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Co-components prevent assigning an effect to a single fulvic molecule. In-vitro activity is not established clinical benefit; preparation and dilution remain essential. This cancer-cell assay does not establish healthy intestinal repair or barrier integrity.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Fulvic acid collection; species, compartment, exposure, co-substrates and manipulation remain explicit.","comparator":null,"unit":null,"notes":"","entity":{"slug":"fulvic-acid","display_name":"Fulvic acid (heterogeneous humic fraction)","entity_type_key":"chemical_species"}},{"dimension":"plain_language","value_text":"A cultured monolayer closed its artificial gap faster.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Integrated safety and microbiota profiling of fulvic acid formulations across in vitro and in vivo models. · 2026 · https://pubmed.ncbi.nlm.nih.gov/41580488/ · DOI 10.1038/s41598-026-37331-2","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"19865cb2-1089-55b9-a1b6-bd85f762b327","evidence_kind":"source_excerpt","locator":"Lines 244-250","start_line":244,"end_line":250,"excerpt":"## fulvic-acid-lovo-scratch\nA cultured monolayer closed its artificial gap faster.\nMLG-A50 increased scratch closure in LoVo-cell assays.\nModel: 2026 MLG-50/MLG-A50 study; fossil extracts contain fulvic fractions plus mineral/polyphenol components, stock pH about 1.97/12.1. Human colorectal adenocarcinoma LoVo cells; dilutions 1:8192 to 1:32768.\nLimitations: Co-components prevent assigning an effect to a single fulvic molecule. In-vitro activity is not established clinical benefit; preparation and dilution remain essential. This cancer-cell assay does not establish healthy intestinal repair or barrier integrity.\nEvidence access: Primary full text\nIntegrated safety and microbiota profiling of fulvic acid formulations across in vitro and in vivo models. · 2026 · https://pubmed.ncbi.nlm.nih.gov/41580488/ · DOI 10.1038/s41598-026-37331-2","model_system":"2026 MLG-50/MLG-A50 study; fossil extracts contain fulvic fractions plus mineral/polyphenol components, stock pH about 1.97/12.1. Human colorectal adenocarcinoma LoVo cells; dilutions 1:8192 to 1:32768.","directness":"reported_statement","verification_status":"source_derived_draft","notes":"Original curation paraphrase; evidence access and experimental limitations specified.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"b00a1818-46e4-52cc-8dfe-a647d5c08ed7","stable_key":"import-788beb7b-7928-5f89-83d4-5556abf3702c","title":"Fulvic acid: mixture identity, mineral chemistry, signaling and cross-nutrient mechanisms (2026-09-19)","document_type":"imported_text","citation_label":"AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text.","file_path":"","sha256":"52c2c3ee6bb23d943a40e1c39dd9de5cca7acd6efa72479cb824149e85cc7968","revision_id":"94dfc01b-c93e-55ff-8f48-bb2e9a1979f6","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}